Seres Therapeutics, INC Form 4 insider transactions

Lisa von Moltke, Executive Vice President and Chief Medical Officer at Seres Therapeutics, sold 977 shares of common stock to cover taxes related to the vesting of restricted stock units.

Seres Therapeutics CEO Eric Shaff acquired shares through restricted stock unit vesting and sold a portion to cover taxes.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer at Seres Therapeutics, sold 735 shares of common stock after the vesting of restricted stock units.

Matthew R. Henn, Chief Scientific Officer of Seres Therapeutics, sold 927 shares of common stock after the vesting of restricted stock units.

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, reports the vesting and sale of restricted stock units to cover taxes.

Matthew Henn, Chief Scientific Officer and EVP of Seres Therapeutics, reports the vesting and sale of restricted stock units to cover taxes.

Thomas DesRosier, Chief Legal Officer and EVP of Seres Therapeutics, reports the vesting and sale of common stock related to restricted stock units.

Seres Therapeutics CEO Eric Shaff reports the vesting and sale of restricted stock units to cover taxes.

Teresa Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, reports the vesting and sale of restricted stock units to cover taxes.

Thomas DesRosier, Chief Legal Officer and EVP of Seres Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, reports the sale of shares to cover taxes related to vesting restricted stock units.

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, sold shares of common stock on August 16, 2024, to cover taxes related to the vesting of restricted stock units.

Seres Therapeutics CEO Eric Shaff reports the acquisition and disposal of common stock, including sales to cover taxes related to vesting restricted stock units.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, sold shares of common stock to cover taxes related to the vesting of restricted stock units.

David S. Ege, Executive Vice President and Chief Technology Officer of Seres Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, sold 24,480 shares of common stock on August 5, 2024, to cover taxes related to the vesting of restricted stock units.

Director Dennis A. Ausiello acquired stock options in Seres Therapeutics, Inc.

Director Kurt Graves acquired 64,564 stock options in Seres Therapeutics on July 1, 2024, vesting quarterly over the next year.

Director Stephen Berenson acquired stock options in Seres Therapeutics, Inc. on July 1, 2024.

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, reports the acquisition and disposal of common stock related to vested restricted stock units.

Seres Therapeutics CEO Eric Shaff reports the acquisition and disposal of common stock and restricted stock units, including sales to cover taxes related to vesting.

Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, exercised restricted stock units and sold a portion of the acquired shares to cover tax obligations.

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, sold 891 shares of common stock on May 15, 2024, to cover taxes related to the vesting of restricted stock units.

David S. Ege, Executive Vice President and Chief Technology Officer of Seres Therapeutics, reports the acquisition and disposition of common stock related to restricted stock units.

Thomas DesRosier, Chief Legal Officer and EVP of Seres Therapeutics, sold 843 shares of common stock on May 15, 2024, to cover taxes related to vesting restricted stock units.

Director Kurt Graves acquired stock options in Seres Therapeutics, Inc.

Director Richard N. Kender acquired stock options for 60,000 shares of Seres Therapeutics at an exercise price of $0.76 on April 4, 2024.

Director Paul Biondi acquired 60,000 stock options in Seres Therapeutics, Inc. on April 4, 2024.

Director Claire Fraser acquired stock options for 60,000 shares of Seres Therapeutics common stock on April 4, 2024.

Director Dere Willard H. acquired 60,000 stock options in Seres Therapeutics, Inc. on April 4, 2024.